The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.
Bart Neyns
Research Funding - Pfizer
Johnny Duerinck
Other Remuneration - Pfizer
Stephanie Du Four
No relevant relationships to disclose
Frank Bouttens
No relevant relationships to disclose
Vincent Verschaeve
No relevant relationships to disclose
Hendrik Everaert
No relevant relationships to disclose
An Van Binst
No relevant relationships to disclose